Literature DB >> 1183140

Propranolol in hypertensive dialysis patients: efficacy and compliance.

W A Briggs, D T Lowenthal, W J Cirksena, W E Price, T P Gibson, W Flamenbaum.   

Abstract

The effect of propranolol therapy on plasma renin activity and blood pressure control was evaluated in 35 uremic patients receiving intermittent center-based outpatient hemodialysis. Patients were determined to be either compliant or noncompliant with therapy based on the steady-state predialysis plasma propranolol concentration. Noncompliance occurred with remarkable frequency and was associated with persistent hyperreninemia and poorly controlled hypertension. Blood pressure control was significantly better in compliant patients, in whom plasma renin activity was generally, but not universally, suppressed. Propranolol can be effectively used in the management of hypertensive dialysis patients, but steady-state plasma propranolol levels should be measured to assess compliance in patients apparently refractory to treatment.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183140     DOI: 10.1002/cpt1975185part1606

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  The hypertensive patient: 5. Compliance with therapy.

Authors:  D L Sackett
Journal:  Can Med Assoc J       Date:  1979-08-04       Impact factor: 8.262

2.  Once daily administration of sustained release propranolol capsules in the treatment of angina pectoris.

Authors:  H Halkin; I Vered; A Saginer; B Rabinowitz
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

3.  Who is taking their tablets?

Authors:  R M Pearson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-18

4.  Electronic pillboxes (MEMS) to assess the relationship between medication adherence and blood pressure control in primary care.

Authors:  Andreas Zeller; Knut Schroeder; Tim J Peters
Journal:  Scand J Prim Health Care       Date:  2007-12       Impact factor: 2.581

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.